Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Pegasparaginase and Erwinia Asparaginase: The Impact of Expensive Chemotherapy

被引：0
|
作者：
Tong, Wing H. [1 ]
van der Sluis, Inge M. [1 ]
Alleman, Cathelijne [2 ]
van Litsenburg, Raphaele R. L. [3 ]
Kaspers, Gertjan [3 ]
Pieters, Rob [1 ]
Uyl-de Groot, Carin A. [2 ]
机构：
[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands
[2] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4227.4227
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4227
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Asparaginase use for the treatment of acute lymphoblastic leukemia
    Barba, Pere
    Luis Dapena, Jose
    Montesinos, Pau
    Rives, Susana
    MEDICINA CLINICA, 2017, 148 (05): : 225 - 231
  • [22] COST-EFFECTIVENESS ANALYSIS OF BLINATUMOMAB FOR ADVANCED ACUTE LYMPHOBLASTIC LEUKEMIA IN JAPAN
    Ozeki, S.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S111 - S111
  • [23] Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study
    Birgitte Klug Albertsen
    Kjeld Schmiegelow
    Henrik Schrøder
    Niels T. Carlsen
    Steen Rosthøj
    Vassilios I. Avramis
    Preben Jakobsen
    Cancer Chemotherapy and Pharmacology, 2002, 50 : 117 - 120
  • [24] Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome:: a case-control study
    Albertsen, BK
    Schmiegelow, K
    Schroder, H
    Carlsen, NT
    Rosthoj, S
    Avramis, VI
    Jakobsen, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (02) : 117 - 120
  • [25] A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia
    Vagrecha, Anshul
    Tao, Vincent
    Corless, Rosemarie
    Colon, Cassandra
    Redner, Arlene
    Atlas, Mark
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (08) : 763 - 769
  • [26] Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
    Sassen, Sebastiaan D. T.
    Mathot, Ron A. A.
    Pieters, Rob
    Kloos, Robin Q. H.
    de Haas, Valerie
    Kaspers, Gertjan J. L.
    van den Bos, Cor
    Tissing, Wim J. E.
    te Loo, Maroeska
    Bierings, Marc B.
    Kollen, Wouter J. W.
    Zwaan, Christian M.
    van der Sluis, Inge M.
    HAEMATOLOGICA, 2017, 102 (03) : 552 - 561
  • [27] ACUTE-LEUKEMIA IN ADULTS - COST-EFFECTIVENESS OF TREATMENT
    VOGEL, LL
    THORUP, OA
    KAISER, DL
    ZIRKLE, JW
    HARLAN, JF
    HESS, CE
    SOUTHERN MEDICAL JOURNAL, 1984, 77 (01) : 51 - 55
  • [28] PEGASPARGASE VERSUS ASPARAGINASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A COST-MINIMIZATION ANALYSIS IN FRANCE
    Lecureuil, C.
    Staginnus, U.
    Robbins, S.
    Ponet, O.
    VALUE IN HEALTH, 2016, 19 (07) : A589 - A590
  • [29] Individualized dosing of asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Silverman, LB
    Supko, JG
    Levy, DE
    Dalton, VK
    Gelber, RD
    Sallan, SE
    BLOOD, 2003, 102 (11) : 224A - 224A
  • [30] Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia
    Tong, Wing H.
    Mesegue, Montserrat
    Dapena, Jose Luis
    Camos, Mireia
    Rives, Susana
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 809 - 811
12345